Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma

Riichiroh Maruyama, Fumihiro Shoji, Tatsuro Okamoto, Tetsuya Miyamoto, Tetsuro Miyake, Tomomi Nakamura, Jiro Ikeda, Yoshiro Aoki, Hiroshi Wataya, Hiroshi Asoh, Yukito Ichinose

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The incidence of malignant pleural mesothelioma (MPM) is expected to increase due to delayed control of occupational exposure to asbestos in Japan. We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM. Methods: From December 2000 to August 2003, 12 patients received the following regimen: CDDP 40 mg/m2, GEM 800 mg/m2 and VNR 20 mg/m2 on days 1 and 8 every 4 weeks. Among the 12 patients, six selected patients underwent an extrapleural pneumonectomy (EP) after a median of three cycles of triplet chemotherapy. Results: The overall response rate for all patients and the response rate for chemotherapy-naive cases were 58 and 67%, respectively. The median survival time and survival rate at 2 years for all patients were 11 months and 50%, respectively. The 2-year survival rates for the patients with and without EP were 83.3 and 16.7%, respectively. Conclusions: Triplet chemotherapy with CDDP, GEM and VNR was thus found to be highly effective for patients with MPM and its toxicity was manageable. A multi-institutional phase II trial is now being planned to establish the effectiveness of this new regimen in chemotherapy-naive patients with MPM.

Original languageEnglish
Pages (from-to)433-438
Number of pages6
JournalJapanese journal of clinical oncology
Volume35
Issue number8
DOIs
Publication statusPublished - Aug 1 2005

Fingerprint

gemcitabine
Cisplatin
Drug Therapy
Pneumonectomy
Survival Rate
vinorelbine
Malignant Mesothelioma
Asbestos
Occupational Exposure
Combination Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Maruyama, R., Shoji, F., Okamoto, T., Miyamoto, T., Miyake, T., Nakamura, T., ... Ichinose, Y. (2005). Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. Japanese journal of clinical oncology, 35(8), 433-438. https://doi.org/10.1093/jjco/hyi127

Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. / Maruyama, Riichiroh; Shoji, Fumihiro; Okamoto, Tatsuro; Miyamoto, Tetsuya; Miyake, Tetsuro; Nakamura, Tomomi; Ikeda, Jiro; Aoki, Yoshiro; Wataya, Hiroshi; Asoh, Hiroshi; Ichinose, Yukito.

In: Japanese journal of clinical oncology, Vol. 35, No. 8, 01.08.2005, p. 433-438.

Research output: Contribution to journalArticle

Maruyama, R, Shoji, F, Okamoto, T, Miyamoto, T, Miyake, T, Nakamura, T, Ikeda, J, Aoki, Y, Wataya, H, Asoh, H & Ichinose, Y 2005, 'Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma', Japanese journal of clinical oncology, vol. 35, no. 8, pp. 433-438. https://doi.org/10.1093/jjco/hyi127
Maruyama, Riichiroh ; Shoji, Fumihiro ; Okamoto, Tatsuro ; Miyamoto, Tetsuya ; Miyake, Tetsuro ; Nakamura, Tomomi ; Ikeda, Jiro ; Aoki, Yoshiro ; Wataya, Hiroshi ; Asoh, Hiroshi ; Ichinose, Yukito. / Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. In: Japanese journal of clinical oncology. 2005 ; Vol. 35, No. 8. pp. 433-438.
@article{3bd5aa86b7214b17ad90c06af9ad3287,
title = "Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma",
abstract = "Background: The incidence of malignant pleural mesothelioma (MPM) is expected to increase due to delayed control of occupational exposure to asbestos in Japan. We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM. Methods: From December 2000 to August 2003, 12 patients received the following regimen: CDDP 40 mg/m2, GEM 800 mg/m2 and VNR 20 mg/m2 on days 1 and 8 every 4 weeks. Among the 12 patients, six selected patients underwent an extrapleural pneumonectomy (EP) after a median of three cycles of triplet chemotherapy. Results: The overall response rate for all patients and the response rate for chemotherapy-naive cases were 58 and 67{\%}, respectively. The median survival time and survival rate at 2 years for all patients were 11 months and 50{\%}, respectively. The 2-year survival rates for the patients with and without EP were 83.3 and 16.7{\%}, respectively. Conclusions: Triplet chemotherapy with CDDP, GEM and VNR was thus found to be highly effective for patients with MPM and its toxicity was manageable. A multi-institutional phase II trial is now being planned to establish the effectiveness of this new regimen in chemotherapy-naive patients with MPM.",
author = "Riichiroh Maruyama and Fumihiro Shoji and Tatsuro Okamoto and Tetsuya Miyamoto and Tetsuro Miyake and Tomomi Nakamura and Jiro Ikeda and Yoshiro Aoki and Hiroshi Wataya and Hiroshi Asoh and Yukito Ichinose",
year = "2005",
month = "8",
day = "1",
doi = "10.1093/jjco/hyi127",
language = "English",
volume = "35",
pages = "433--438",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma

AU - Maruyama, Riichiroh

AU - Shoji, Fumihiro

AU - Okamoto, Tatsuro

AU - Miyamoto, Tetsuya

AU - Miyake, Tetsuro

AU - Nakamura, Tomomi

AU - Ikeda, Jiro

AU - Aoki, Yoshiro

AU - Wataya, Hiroshi

AU - Asoh, Hiroshi

AU - Ichinose, Yukito

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Background: The incidence of malignant pleural mesothelioma (MPM) is expected to increase due to delayed control of occupational exposure to asbestos in Japan. We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM. Methods: From December 2000 to August 2003, 12 patients received the following regimen: CDDP 40 mg/m2, GEM 800 mg/m2 and VNR 20 mg/m2 on days 1 and 8 every 4 weeks. Among the 12 patients, six selected patients underwent an extrapleural pneumonectomy (EP) after a median of three cycles of triplet chemotherapy. Results: The overall response rate for all patients and the response rate for chemotherapy-naive cases were 58 and 67%, respectively. The median survival time and survival rate at 2 years for all patients were 11 months and 50%, respectively. The 2-year survival rates for the patients with and without EP were 83.3 and 16.7%, respectively. Conclusions: Triplet chemotherapy with CDDP, GEM and VNR was thus found to be highly effective for patients with MPM and its toxicity was manageable. A multi-institutional phase II trial is now being planned to establish the effectiveness of this new regimen in chemotherapy-naive patients with MPM.

AB - Background: The incidence of malignant pleural mesothelioma (MPM) is expected to increase due to delayed control of occupational exposure to asbestos in Japan. We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM. Methods: From December 2000 to August 2003, 12 patients received the following regimen: CDDP 40 mg/m2, GEM 800 mg/m2 and VNR 20 mg/m2 on days 1 and 8 every 4 weeks. Among the 12 patients, six selected patients underwent an extrapleural pneumonectomy (EP) after a median of three cycles of triplet chemotherapy. Results: The overall response rate for all patients and the response rate for chemotherapy-naive cases were 58 and 67%, respectively. The median survival time and survival rate at 2 years for all patients were 11 months and 50%, respectively. The 2-year survival rates for the patients with and without EP were 83.3 and 16.7%, respectively. Conclusions: Triplet chemotherapy with CDDP, GEM and VNR was thus found to be highly effective for patients with MPM and its toxicity was manageable. A multi-institutional phase II trial is now being planned to establish the effectiveness of this new regimen in chemotherapy-naive patients with MPM.

UR - http://www.scopus.com/inward/record.url?scp=24944478360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944478360&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyi127

DO - 10.1093/jjco/hyi127

M3 - Article

C2 - 16006571

AN - SCOPUS:24944478360

VL - 35

SP - 433

EP - 438

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

ER -